Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparability of Felzartamab in Healthy Chinese Males
NCT06285201Phase 1Completed
- Sponsor
- TJ Biopharma
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of felzartamab in multiple myeloma (MM) and membranous nephropathy (MN) (2 arms), sponsored by TJ Biopharma. Primary endpoint: Primary Pharmacokinetic Endpoint. Started Mar 2024; status: completed.
02
Drugs
felzartamab
03
Conditions
multiple myeloma (MM)membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT06285201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285201.